Evidence map›Paper›PMID 39126233›Full record

ArticleMolecular genetics & genomic medicine2024

Hereditary breast cancer next-generation sequencing panel evaluation in the south region of Brazil: A novel BRCA2 candidate pathogenic variant is reported.

Cesar Augusto B Duarte, Carlos Alberto Dos Santos, Cristine Domingues D de Oliveira, Cleverton César Spautz, Laura Masami Sumita, Sueli Massumi Nakatani

Abstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Identification and Computational Analysis ofMedical sciences (Basel, Switzerland) · 2025
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Cesar Augusto B DuarteResearch and Development Division, Genoprimer Diagnóstico Molecular, Curitiba, Paraná, Brazil.ORCID https://orcid.org/0009-0004-8864-3357
Carlos Alberto Dos SantosMolecular Biology Clinical Laboratory, Clinimol Diagnóstico Molecular, São Paulo, São Paulo, Brazil.
Cristine Domingues D de OliveiraMolecular Biology Clinical Laboratory, Clinimol Diagnóstico Molecular, São Paulo, São Paulo, Brazil.
Cleverton César SpautzDepartment of Surgery, Hospital Nossa Senhora das Graças, Curitiba, Paraná, Brazil.
Laura Masami SumitaMolecular Biology Clinical Laboratory, Clinimol Diagnóstico Molecular, São Paulo, São Paulo, Brazil.
Sueli Massumi NakataniResearch and Development Division, Genoprimer Diagnóstico Molecular, Curitiba, Paraná, Brazil.

Funding

None.
6 · The paper itself

Abstract

backgroundIn this article, we delineate a loosely selected cohort comprising patients with a history of early-onset breast cancer and/or a familial occurrence of cancer. The aim of this study was to gain insights into the presence of breast cancer-related gene variants in a population from a micro-region in southern Brazil, specifically the Metropolitan Region of Curitiba. This area exhibits a highly genetically mixed population, mirroring the general characteristics of the Brazilian people.

methodsComprehensive next-generation sequencing (NGS) multigene panel testing was conducted on 12 patients from the region, utilizing three different library preparation methods.

resultsTwo pathogenic variants and one candidate pathogenic variant were identified: BRCA2 c.8878C>T, p.Gln2960Ter; CHEK2 c.1100del, p.Thr367Metfs15, and BRCA2 c.3482dup, p.Asp1161Glufs3.

conclusionBRCA2 c.3482dup, a novel candidate pathogenic variant, previously unpublished, is reported. The prevalence of pathogenic variants in this small cohort is similar to that described in the literature. All different library preparation methods were equally proficient in enabling the detection of these variants.

Indexed as

BRCA2 ProteinBreast NeoplasmsCheckpoint Kinase 2High-Throughput Nucleotide SequencingAdultBrazilFemaleGenetic Predisposition to DiseaseGenetic TestingHumansMiddle AgedBRCA2 ProteinBRCA2 protein, humanCheckpoint Kinase 2CHEK2 protein, humanBRCA2 mutationhereditary breast cancernext‐generation sequencingvariant interpretation

Identifiers

PMID39126233
PMCPMC11316010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.